Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

The regulation of acetylation and stability of HMGA2 via the HBXIP-activated Akt–PCAF pathway in promotion of esophageal squamous cell carcinoma growth

Open access
Wu, Yue, Wang, Xue, Xu, Feifei, Zhang, Lu, Wang, Tianjiao, Fu, Xueli, Jin, Tianzhi, Zhang, Weiying, Ye, Lihong · 2020 · Nucleic Acids Research

Abstract

High-mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that plays essential roles in embryonic development and cancer progression. However, the mechanism of HMGA2 regulation remains largely uncharacterized. Here, we demonstrate that HMGA2 can be modulated by hepatitis B X-interacting protein (HBXIP), an oncogenic transcriptional coactivator, in esophageal squamous cell carcinoma (ESCC). HMGA2 expression was positively associated with HBXIP expression in clinical ESCC tissues, and their high levels were associated with advanced tumor stage and reduced overall and disease-free survival. We found that oncogenic HBXIP could posttranslationally upregulate HMGA2 protein level in ESCC cells. HBXIP induced HMGA2 acetylation at the lysine 26 (K26), resulting in HMGA2 protein accumulation. In this process, HBXIP increased the acetyltransferase p300/CBP-associated factor (PCAF) phosphorylation and activation via the Akt pathway, then PCAF directly interacted with HMGA2, leading to HMGA2 acetylation in the cells. HMGA2 K26 acetylation enhanced its DNA binding capacity and blocked its ubiquitination and then inhibited proteasome-dependent degradation. Functionally, HBXIP-stabilized HMGA2 could promote ESCC cell growth in vitro and in vivo. Strikingly, aspirin suppressed ESCC growth by inhibiting HBXIP and HMGA2. Collectively, our findings disclose a new mechanism for the posttranslational regulation of HMGA2 mediated by HBXIP in ESCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gkaa232

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. HMGA2 is upregulated by HBXIP in human ESCC tissues and cells. (A) HMGA2 and HBXIP expressions were assessed by immunohistochemical staining in an esophageal tissue microarray containing 43 normal esophageal tissues and 151 ESCC tissues from Shantou University Medical College between February 2011 and November 2016. Scale bars, 50 μm. (B) Heatmap view of HMGA2 and HBXIP expressions of the esophageal tissue microarray used in (A). Numbers 0, 1, 2 and 3 represent negative, week, moderate, and intense staining, respectively. (C and D) Kaplan–Meier plots of the overall survival (C) and disease-free survival (D) rates of 151 ESCC patients stratified according to HMGA2 expression from the esophageal tissue microarray containing 43 normal esophageal tissues and 151 ESCC tissues used in (A). (E and F) Kaplan–Meier plots of the overall survival (E) and disease-free survival (F) rates of 151 ESCC patients stratified according to HBXIP expression from the esophageal tissue microarray containing 43 normal esophageal tissues and 151 ESCC tissues used in (A). (G) HMGA2 and HBXIP expressions were measured by western blotting in four ESCC cell lines. (H) Real-time PCR analysis of HBXIP and HMGA2 mRNA levels in KYSE180 cells transfected with the pCMV or pCMV-HBXIP plasmids and in KYSE2 cells transfected with control siRNA (siCtrl) or HBXIP siRNA (siHBXIP). Each bar shows the means ± SD (n = 3). (I) The HBXIP and HMGA2 protein levels were measured by western blotting in KYSE180 cells transiently transfected with pCMV or pCMV-HBXIP plasmids and KYSE2 cells transfected with siRNA (siCtrl) or HBXIP siRNA (siHBXIP). Statistically significant differences are indicated: *P < 0.05, **P < 0.01 and ***P < 0.001; NS, not significant; Student's t-test.
Figure 1. HMGA2 is upregulated by HBXIP in human ESCC tissues and cells. (A) HMGA2 and HBXIP expressions were assessed by immunohistochemical staining in an esophageal tissue microarray containing 43 normal esophageal tissues and 151 ESCC tissues from Shantou University Medical College between February 2011 and November 2016. Scale bars, 50 μm. (B) Heatmap view of HMGA2 and HBXIP expressions of the esophageal tissue microarray used in (A). Numbers 0, 1, 2 and 3 represent negative, week, moderate, and intense staining, respectively. (C and D) Kaplan–Meier plots of the overall survival (C) and disease-free survival (D) rates of 151 ESCC patients stratified according to HMGA2 expression from the esophageal tissue microarray containing 43 normal esophageal tissues and 151 ESCC tissues used in (A). (E and F) Kaplan–Meier plots of the overall survival (E) and disease-free survival (F) rates of 151 ESCC patients stratified according to HBXIP expression from the esophageal tissue microarray containing 43 normal esophageal tissues and 151 ESCC tissues used in (A). (G) HMGA2 and HBXIP expressions were measured by western blotting in four ESCC cell lines. (H) Real-time PCR analysis of HBXIP and HMGA2 mRNA levels in KYSE180 cells transfected with the pCMV or pCMV-HBXIP plasmids and in KYSE2 cells transfected with control siRNA (siCtrl) or HBXIP siRNA (siHBXIP). Each bar shows the means ± SD (n = 3). (I) The HBXIP and HMGA2 protein levels were measured by western blotting in KYSE180 cells transiently transfected with pCMV or pCMV-HBXIP plasmids and KYSE2 cells transfected with siRNA (siCtrl) or HBXIP siRNA (siHBXIP). Statistically significant differences are indicated: *P < 0.05, **P < 0.01 and ***P < 0.001; NS, not significant; Student's t-test.CC BY-NC · PubMed Central
Figure 2. HBXIP contributes to HMGA2 stabilization through inducing its K26 acetylation. (A) Degradation of HMGA2 protein was measured in KYSE180 cells treated with 100 μg/ml CHX for the indicated periods after transient transfection with pCMV or pCMV-HBXIP vectors. The HMGA2 intensity normalized to β-actin was plotted. Each bar shows the means ± SD (n = 3). (B) Exogenous FLAG-HMGA2 was measured by western blotting in HEK293T cells transiently transfected with pCMV-HMGA2 co-transfected with pcDNA or pcDNA-HBXIP plasmids. The FLAG-HMGA2 protein level was detected using the anti-FLAG antibody. (C) Endogenous HMGA2 in KYSE180 cells were measured by western blotting after treatment with 100 μg/ml CHX along with different concentrations of TSA for 18 h or 1 μM TSA for the indicated periods. (D) Exogenous FLAG-HMGA2 was immunoprecipitated with FLAG beads in HEK293T cells, and then the acetylation of HMGA2 protein in precipitation was measured by western blotting with an anti-acetylated-lysine antibody. The cells were transiently transfected with the indicated plasmids. (E) A Schematic of FLAG-tagged full-length or serial deletion mutant HMGA2. (F) HEK293T were transfected with FLAG-tagged full-length HMGA2 expression vectors (WT) or serial deletion mutant HMGA2 expression vectors (D1, D2 or D3). Cell lysates were immunoprecipitated with FLAG beads, followed by western blotting with anti-FLAG and anti-acetylated-lysine antibodies. (G) FLAG-tagged WT, K26R, K34R, or K26/34R of HMGA2 along with pcDNA or pcDNA-HBXIP plasmids was transfected into HEK293T cells. Exogenous FLAG-tagged HMGA2 was immunoprecipitated with FLAG beads, and then acetylation levels of HMGA2 protein in precipitation were tested by western blotting with an anti-acetylated-lysine antibody. (H) The stabilities of WT and K26R mutant HMGA2 were measured by western blotting. HEK293T cells expressing FLAG-tagged WT or K26R mutant HMGA2 were treated with CHX for the indicated periods. Each bar shows the means ± SD (n = 3). (I) Ectopically expressed FLAG-tagged WT and K26R mutant HMGA2 levels were measured after the treatment of 1 μM TSA for 18 h in KYSE180 cells by western blotting with an anti-FLAG antibody. The upper panel is the quantification of the intensity relative to β-actin. Each bar shows the means ± SD (n = 3). (J) Ectopically expressed FLAG-tagged WT and K26R mutant HMGA2 levels were measured in KYSE180 cells transfected with pcDNA or pcDNA-HBXIP vectors by western blotting with an anti-FLAG antibody. The upper panel is the quantification of the intensity relative to β-actin. Each bar shows the means ± SD (n = 3). All experiments were repeated at least three times. Statistically significant differences are indicated: **P < 0.01 and ***P < 0.001; NS not significant; Student's t-test.
Figure 2. HBXIP contributes to HMGA2 stabilization through inducing its K26 acetylation. (A) Degradation of HMGA2 protein was measured in KYSE180 cells treated with 100 μg/ml CHX for the indicated periods after transient transfection with pCMV or pCMV-HBXIP vectors. The HMGA2 intensity normalized to β-actin was plotted. Each bar shows the means ± SD (n = 3). (B) Exogenous FLAG-HMGA2 was measured by western blotting in HEK293T cells transiently transfected with pCMV-HMGA2 co-transfected with pcDNA or pcDNA-HBXIP plasmids. The FLAG-HMGA2 protein level was detected using the anti-FLAG antibody. (C) Endogenous HMGA2 in KYSE180 cells were measured by western blotting after treatment with 100 μg/ml CHX along with different concentrations of TSA for 18 h or 1 μM TSA for the indicated periods. (D) Exogenous FLAG-HMGA2 was immunoprecipitated with FLAG beads in HEK293T cells, and then the acetylation of HMGA2 protein in precipitation was measured by western blotting with an anti-acetylated-lysine antibody. The cells were transiently transfected with the indicated plasmids. (E) A Schematic of FLAG-tagged full-length or serial deletion mutant HMGA2. (F) HEK293T were transfected with FLAG-tagged full-length HMGA2 expression vectors (WT) or serial deletion mutant HMGA2 expression vectors (D1, D2 or D3). Cell lysates were immunoprecipitated with FLAG beads, followed by western blotting with anti-FLAG and anti-acetylated-lysine antibodies. (G) FLAG-tagged WT, K26R, K34R, or K26/34R of HMGA2 along with pcDNA or pcDNA-HBXIP plasmids was transfected into HEK293T cells. Exogenous FLAG-tagged HMGA2 was immunoprecipitated with FLAG beads, and then acetylation levels of HMGA2 protein in precipitation were tested by western blotting with an anti-acetylated-lysine antibody. (H) The stabilities of WT and K26R mutant HMGA2 were measured by western blotting. HEK293T cells expressing FLAG-tagged WT or K26R mutant HMGA2 were treated with CHX for the indicated periods. Each bar shows the means ± SD (n = 3). (I) Ectopically expressed FLAG-tagged WT and K26R mutant HMGA2 levels were measured after the treatment of 1 μM TSA for 18 h in KYSE180 cells by western blotting with an anti-FLAG antibody. The upper panel is the quantification of the intensity relative to β-actin. Each bar shows the means ± SD (n = 3). (J) Ectopically expressed FLAG-tagged WT and K26R mutant HMGA2 levels were measured in KYSE180 cells transfected with pcDNA or pcDNA-HBXIP vectors by western blotting with an anti-FLAG antibody. The upper panel is the quantification of the intensity relative to β-actin. Each bar shows the means ± SD (n = 3). All experiments were repeated at least three times. Statistically significant differences are indicated: **P < 0.01 and ***P < 0.001; NS not significant; Student's t-test.CC BY-NC · PubMed Central
Figure 3. The acetylase PCAF is responsible for HMGA2 acetylation at K26 by HBXIP. (A) FLAG-HMGA2 vectors accompanied by the indicated plasmids or siRNAs against a variety of acetyltransferases were transfected into KYSE2 cells. Exogenous FLAG-HMGA2 was immunoprecipitated with FLAG beads, and then the acetylation of HMGA2 protein in precipitation was tested by western blotting with an anti-acetylated-lysine antibody. (B) FLAG-HMGA2 vectors were cotransfected with or without GFP-PCAF plasmids into KYSE180 cells. Exogenous FLAG-HMGA2 was immunoprecipitated with FLAG beads, and then the acetylation of HMGA2 protein in precipitation was tested by western blotting with the anti-AcK26-HMGA2 antibody. (C) Co-IP assays were performed to detect the interaction of endogenous PCAF with HMGA2 in KYSE180 cells with anti-HMGA2 antibody or control IgG. (D) GFP-PCAF and FLAG-HMGA2 plasmids were co-transfected into HEK293T cells, immunoprecipitated with FLAG beads followed by western blotting with anti-GFP and anti-FLAG antibodies. (E) HEK293T cells were co-transfected with FLAG-PCAF and GFP-HMGA2 plasmids, immunoprecipitated with FLAG beads followed by western blotting with anti-GFP and anti-FLAG antibodies. (F) The co-localization of endogenous PCAF and HMGA2 in KYSE180 cells was examined by confocal microscopy. KYSE180 cells were stained with an anti-PCAF monoclonal antibody (green) and an anti-HMGA2 polyclonal antibody (red). Nuclei were stained with DAPI (blue), followed by visualization with confocal microscopy. Scale bars, 10 μm. (G) Endogenous HMGA2 was determined by western blotting in KYSE180 cells transfected with the indicated plasmids. (H) FLAG-K26R mutant HMGA2 vector was co-transfected with or without GFP-PCAF into KYSE180 cells. The levels of FLAG-K26R mutant HMGA2 were measured by western blotting with an anti-FLAG antibody. (I) Western blotting analysis of endogenous HMGA2 protein in KYSE2 cells. The cells were treated with CHX for the indicated periods after transfection with control siRNA (siCtrl) or PCAF siRNA#1 (siPCAF#1). (J) Endogenous HMGA2 protein levels were detected by western blotting in KYSE180 cells cotransfected with pCMV-HBXIP plasmids and/or PCAF siRNA#1. All experiments were repeated at least three times.
Figure 3. The acetylase PCAF is responsible for HMGA2 acetylation at K26 by HBXIP. (A) FLAG-HMGA2 vectors accompanied by the indicated plasmids or siRNAs against a variety of acetyltransferases were transfected into KYSE2 cells. Exogenous FLAG-HMGA2 was immunoprecipitated with FLAG beads, and then the acetylation of HMGA2 protein in precipitation was tested by western blotting with an anti-acetylated-lysine antibody. (B) FLAG-HMGA2 vectors were cotransfected with or without GFP-PCAF plasmids into KYSE180 cells. Exogenous FLAG-HMGA2 was immunoprecipitated with FLAG beads, and then the acetylation of HMGA2 protein in precipitation was tested by western blotting with the anti-AcK26-HMGA2 antibody. (C) Co-IP assays were performed to detect the interaction of endogenous PCAF with HMGA2 in KYSE180 cells with anti-HMGA2 antibody or control IgG. (D) GFP-PCAF and FLAG-HMGA2 plasmids were co-transfected into HEK293T cells, immunoprecipitated with FLAG beads followed by western blotting with anti-GFP and anti-FLAG antibodies. (E) HEK293T cells were co-transfected with FLAG-PCAF and GFP-HMGA2 plasmids, immunoprecipitated with FLAG beads followed by western blotting with anti-GFP and anti-FLAG antibodies. (F) The co-localization of endogenous PCAF and HMGA2 in KYSE180 cells was examined by confocal microscopy. KYSE180 cells were stained with an anti-PCAF monoclonal antibody (green) and an anti-HMGA2 polyclonal antibody (red). Nuclei were stained with DAPI (blue), followed by visualization with confocal microscopy. Scale bars, 10 μm. (G) Endogenous HMGA2 was determined by western blotting in KYSE180 cells transfected with the indicated plasmids. (H) FLAG-K26R mutant HMGA2 vector was co-transfected with or without GFP-PCAF into KYSE180 cells. The levels of FLAG-K26R mutant HMGA2 were measured by western blotting with an anti-FLAG antibody. (I) Western blotting analysis of endogenous HMGA2 protein in KYSE2 cells. The cells were treated with CHX for the indicated periods after transfection with control siRNA (siCtrl) or PCAF siRNA#1 (siPCAF#1). (J) Endogenous HMGA2 protein levels were detected by western blotting in KYSE180 cells cotransfected with pCMV-HBXIP plasmids and/or PCAF siRNA#1. All experiments were repeated at least three times.CC BY-NC · PubMed Central
Figure 4. The Akt pathway activates the acetylase PCAF to promote HMGA2 acetylation mediated by HBXIP. (A) Co-IP assays were performed to examine the interaction of exogenous FLAG-PCAF with GFP-HMGA2 in HEK293T cells. GFP-HMGA2 and FLAG-PCAF along with pcDNA or pcDNA-HBXIP plasmids were coexpressed into HEK293T, immunoprecipitated with FLAG beads, and detected with indicated antibodies. (B) KYSE180 cells were transiently transfected with FLAG-PCAF along with pcDNA or pcDNA-HBXIP plasmids. Exogenous FLAG-PCAF was immunoprecipitated with FLAG beads from cell lysates, and then the phosphorylation of PCAF protein in precipitation was tested by western blotting with an anti-phospho-serine antibody. (C) KYSE2 cells were transiently transfected with FLAG-PCAF along with control siRNA (siCtrl) or HBXIP siRNA (siHBXIP). Exogenous FLAG-PCAF was immunoprecipitated with FLAG beads from cell lysates, and then the phosphorylation of PCAF protein in precipitation was examined by western blotting using an anti-phospho-serine antibody. (D) KYSE180 cells were transiently transfected with FLAG-PCAF along with pcDNA or pcDNA-HBXIP plasmids and treated with AKTi (GSK690693, 10 μM), ERKi (PD98059, 10 μM) or p38i (SB202190, 10 μM) for 6 h. Exogenous FLAG-PCAF was immunoprecipitated with FLAG beads from cell lysates, and then the phosphorylation of PCAF protein in precipitation was examined by western blotting with an anti-phospho-serine antibody. (E) KYSE180 cells were transiently transfected with FLAG-PCAF along with pcDNA or pcDNA-HBXIP plasmids and treated with or without AKTi (GSK690693, 10 μM) for 6 h. The interaction of HMGA2 with PCAF and the phosphorylation level of PCAF were detected by a Co-IP assay using FLAG beads followed by western blotting with anti-HMGA2 and anti-phospho-serine antibodies. (F) KYSE180 cells were transiently transfected with FLAG-HMGA2 along with the indicated plasmids and treated with or without AKTi (GSK690693, 10 μM) for 6 h. Exogenous FLAG-HMGA2 was immunoprecipitated with FLAG beads from cell lysates, and then the acetylation of HMGA2 protein in precipitation was tested by western blotting with an anti-acetylated-lysine antibody. All experiments were repeated at least three times.
Figure 4. The Akt pathway activates the acetylase PCAF to promote HMGA2 acetylation mediated by HBXIP. (A) Co-IP assays were performed to examine the interaction of exogenous FLAG-PCAF with GFP-HMGA2 in HEK293T cells. GFP-HMGA2 and FLAG-PCAF along with pcDNA or pcDNA-HBXIP plasmids were coexpressed into HEK293T, immunoprecipitated with FLAG beads, and detected with indicated antibodies. (B) KYSE180 cells were transiently transfected with FLAG-PCAF along with pcDNA or pcDNA-HBXIP plasmids. Exogenous FLAG-PCAF was immunoprecipitated with FLAG beads from cell lysates, and then the phosphorylation of PCAF protein in precipitation was tested by western blotting with an anti-phospho-serine antibody. (C) KYSE2 cells were transiently transfected with FLAG-PCAF along with control siRNA (siCtrl) or HBXIP siRNA (siHBXIP). Exogenous FLAG-PCAF was immunoprecipitated with FLAG beads from cell lysates, and then the phosphorylation of PCAF protein in precipitation was examined by western blotting using an anti-phospho-serine antibody. (D) KYSE180 cells were transiently transfected with FLAG-PCAF along with pcDNA or pcDNA-HBXIP plasmids and treated with AKTi (GSK690693, 10 μM), ERKi (PD98059, 10 μM) or p38i (SB202190, 10 μM) for 6 h. Exogenous FLAG-PCAF was immunoprecipitated with FLAG beads from cell lysates, and then the phosphorylation of PCAF protein in precipitation was examined by western blotting with an anti-phospho-serine antibody. (E) KYSE180 cells were transiently transfected with FLAG-PCAF along with pcDNA or pcDNA-HBXIP plasmids and treated with or without AKTi (GSK690693, 10 μM) for 6 h. The interaction of HMGA2 with PCAF and the phosphorylation level of PCAF were detected by a Co-IP assay using FLAG beads followed by western blotting with anti-HMGA2 and anti-phospho-serine antibodies. (F) KYSE180 cells were transiently transfected with FLAG-HMGA2 along with the indicated plasmids and treated with or without AKTi (GSK690693, 10 μM) for 6 h. Exogenous FLAG-HMGA2 was immunoprecipitated with FLAG beads from cell lysates, and then the acetylation of HMGA2 protein in precipitation was tested by western blotting with an anti-acetylated-lysine antibody. All experiments were repeated at least three times.CC BY-NC · PubMed Central
Figure 5. HMGA2 K26 acetylation enhances its DNA binding ability and predicts a poor prognosis of ESCC patients. (A) KYSE180 cells were transiently transfected with FLAG-HMGA2-WT, FLAG-HMGA2-K26R, FLAG-HMGA2-K26Q, FLAG-HMGA2-WT along with FLAG-PCAF, or FLAG-HMGA2-WT along with PCAF small interfering RNA (siRNA). Cell lysates from these treatments were prepared and subjected to western blotting with indicated antibodies. (B) KYSE180 cells transfected with the indicated plasmids were subjected to ChIP assays with control IgG or an anti-FLAG antibody. The occupancy of HMGA2 in the promoters of cyclin A was examined by qRT-PCR. Each bar shows the means ± SD (n = 3). (C) KYSE180 cells transfected with the indicated plasmids were subjected to ChIP assays with control IgG or an anti-FLAG antibody. The occupancy of HMGA2 in the promoters of SOX2 was examined by qRT-PCR. Each bar shows the means ± SD (n = 3). (D) Monolayer colony-formation assay of KYSE180 cells transfected with the indicated plasmids. (E) Colony forming efficiency of KYSE180 cells expressing the indicated vectors. Each bar shows the means ± SD (n = 3). (F) HMGA2 K26 acetylation was assessed by immunohistochemical staining in 10 normal esophageal tissues and 124 ESCC tissues from human ESCC tissue microarrays. Scale bars, 50 μm. (G) The acetylation level of HMGA2-K26 was analyzed based on pathological grade. Statistically significant differences are indicated: **P < 0.01, and ***P < 0.001; Student's t-test.
Figure 5. HMGA2 K26 acetylation enhances its DNA binding ability and predicts a poor prognosis of ESCC patients. (A) KYSE180 cells were transiently transfected with FLAG-HMGA2-WT, FLAG-HMGA2-K26R, FLAG-HMGA2-K26Q, FLAG-HMGA2-WT along with FLAG-PCAF, or FLAG-HMGA2-WT along with PCAF small interfering RNA (siRNA). Cell lysates from these treatments were prepared and subjected to western blotting with indicated antibodies. (B) KYSE180 cells transfected with the indicated plasmids were subjected to ChIP assays with control IgG or an anti-FLAG antibody. The occupancy of HMGA2 in the promoters of cyclin A was examined by qRT-PCR. Each bar shows the means ± SD (n = 3). (C) KYSE180 cells transfected with the indicated plasmids were subjected to ChIP assays with control IgG or an anti-FLAG antibody. The occupancy of HMGA2 in the promoters of SOX2 was examined by qRT-PCR. Each bar shows the means ± SD (n = 3). (D) Monolayer colony-formation assay of KYSE180 cells transfected with the indicated plasmids. (E) Colony forming efficiency of KYSE180 cells expressing the indicated vectors. Each bar shows the means ± SD (n = 3). (F) HMGA2 K26 acetylation was assessed by immunohistochemical staining in 10 normal esophageal tissues and 124 ESCC tissues from human ESCC tissue microarrays. Scale bars, 50 μm. (G) The acetylation level of HMGA2-K26 was analyzed based on pathological grade. Statistically significant differences are indicated: **P < 0.01, and ***P < 0.001; Student's t-test.CC BY-NC · PubMed Central
Figure 6. HMGA2 acetylation by HBXIP inhibits its ubiquitination to stabilize HMGA2. (A) HEK293T cells were transfected with FLAG-HMGA2 and treated with 40 μM proteasome inhibitor MG-132 for 6 h. Exogenous FLAG-HMGA2 was immunoprecipitated with FLAG beads in HEK293T cells, and then the ubiquitylation level of HMGA2 protein in precipitation was tested by western blotting with an anti-ubiquitin antibody. (B) Endogenous HMGA2 level was detected by western blotting in KYSE180 cells treated with or without 40 μM proteasome inhibitor MG-132 for the indicated periods. (C) Exogenous FLAG-tagged WT and K26R mutant HMGA2 were immunoprecipitated with FLAG beads in HEK293T cells pretreated with 40 μM proteasome inhibitor MG-132 for 6 h, and then the ubiquitylation level of HMGA2 protein in precipitation was tested by western blotting with an anti-ubiquitin antibody. (D) Exogenous FLAG-tagged WT, K26R, or K26Q mutant HMGA2 was immunoprecipitated with FLAG beads in HEK293T cells, and then the ubiquitylation level of HMGA2 protein in precipitation was tested by Western blotting with an anti-ubiquitin antibody. The cells were treated with or without TSA for 12 h and then treated with 40 μM proteasome inhibitor MG-132 for additional 6 h. (E) The quantification of the polyubiquitination intensity relative to immunoprecipitated FLAG-HMGA2 in Figure 6D. Each bar shows the means ± SD (n = 3). (F and G) Endogenous HMGA2 level was detected by western blotting in KYSE2 cells (F) and KYSE450 cells (G) transfected with control siRNA (siCtrl) or HBXIP siRNA (siHBXIP) for 40 h and then treated with 40 μM proteasome inhibitor MG-132 for additional 6 h. (H) KYSE2 cells were transfected with control siRNA (siCtrl) or HBXIP siRNA (siHBXIP) for 40 h and then treated with 40 μM proteasome inhibitor MG-132 for additional 6 h. Exogenous FLAG-HMGA2 was immunoprecipitated with FLAG beads from cell lysates, and then the ubiquitylation level of HMGA2 protein in precipitation was tested by western blotting with an anti-ubiquitin antibody. (I) Exogenous FLAG-tagged WT, K26R or K26Q mutant HMGA2 were immunoprecipitated with FLAG beads in HEK293T cells transfected with or without pcDNA-HBXIP plasmids, and then the ubiquitylation level and acetylation level of HMGA2 protein in precipitation were tested by western blotting with anti-ubiquitin and anti-acetylated lysine antibodies, respectively. All experiments were repeated at least three times. Statistically significant differences are indicated: **P < 0.01; NS, not significant; Student's t-test.
Figure 6. HMGA2 acetylation by HBXIP inhibits its ubiquitination to stabilize HMGA2. (A) HEK293T cells were transfected with FLAG-HMGA2 and treated with 40 μM proteasome inhibitor MG-132 for 6 h. Exogenous FLAG-HMGA2 was immunoprecipitated with FLAG beads in HEK293T cells, and then the ubiquitylation level of HMGA2 protein in precipitation was tested by western blotting with an anti-ubiquitin antibody. (B) Endogenous HMGA2 level was detected by western blotting in KYSE180 cells treated with or without 40 μM proteasome inhibitor MG-132 for the indicated periods. (C) Exogenous FLAG-tagged WT and K26R mutant HMGA2 were immunoprecipitated with FLAG beads in HEK293T cells pretreated with 40 μM proteasome inhibitor MG-132 for 6 h, and then the ubiquitylation level of HMGA2 protein in precipitation was tested by western blotting with an anti-ubiquitin antibody. (D) Exogenous FLAG-tagged WT, K26R, or K26Q mutant HMGA2 was immunoprecipitated with FLAG beads in HEK293T cells, and then the ubiquitylation level of HMGA2 protein in precipitation was tested by Western blotting with an anti-ubiquitin antibody. The cells were treated with or without TSA for 12 h and then treated with 40 μM proteasome inhibitor MG-132 for additional 6 h. (E) The quantification of the polyubiquitination intensity relative to immunoprecipitated FLAG-HMGA2 in Figure 6D. Each bar shows the means ± SD (n = 3). (F and G) Endogenous HMGA2 level was detected by western blotting in KYSE2 cells (F) and KYSE450 cells (G) transfected with control siRNA (siCtrl) or HBXIP siRNA (siHBXIP) for 40 h and then treated with 40 μM proteasome inhibitor MG-132 for additional 6 h. (H) KYSE2 cells were transfected with control siRNA (siCtrl) or HBXIP siRNA (siHBXIP) for 40 h and then treated with 40 μM proteasome inhibitor MG-132 for additional 6 h. Exogenous FLAG-HMGA2 was immunoprecipitated with FLAG beads from cell lysates, and then the ubiquitylation level of HMGA2 protein in precipitation was tested by western blotting with an anti-ubiquitin antibody. (I) Exogenous FLAG-tagged WT, K26R or K26Q mutant HMGA2 were immunoprecipitated with FLAG beads in HEK293T cells transfected with or without pcDNA-HBXIP plasmids, and then the ubiquitylation level and acetylation level of HMGA2 protein in precipitation were tested by western blotting with anti-ubiquitin and anti-acetylated lysine antibodies, respectively. All experiments were repeated at least three times. Statistically significant differences are indicated: **P < 0.01; NS, not significant; Student's t-test.CC BY-NC · PubMed Central
Figure 7. Stable accumulation of oncogenic HMGA2 mediated by HBXIP promotes target gene expression and ESCC growth. (A) Real-time PCR analysis of HMGA2, HBXIP, cyclin A, SOX2, and hTERT mRNA levels in KYSE180 cells separately transfected with pCMV vectors, pCMV-HMGA2 vectors, or cotransfected with pCMV-HMGA2 and pSilencer-HBXIP vectors. Each bar shows the means ± SD (n = 3). (B) Monolayer colony-formation assay of KYSE180 cells transfected with the indicated plasmids. (C) EdU incorporation assays were used to assess EdU-positive cells among KYSE180 cells expressing the indicated vectors. Scale bars, 100 μm. (D) The curves of tumor growth in nude mice transplanted with KYSE180 cells is shown. Each bar shows the means ± SD (each group, n = 6). (E) Imaging of the tumors derived from nude mice transplanted with KYSE180 cells pretreated with indicated plasmids. (F) Weights of tumors in each group were shown. Each bar shows the means ± SD (each group, n = 6). (G) The expression levels of Ki67 and the statistics of Ki67-positive cells from above tumor tissues were examined by immunohistochemical assay. Scale bars, 50 μm. Each bar shows the means ± SD (n = 3). (H) The levels of HMGA2, HBXIP, CyclinA, SOX2 and hTERT from above tumor tissues were detected by western blotting. All experiments were repeated at least three times. Statistically significant differences are indicated: *P < 0.05, **P < 0.01 and ***P < 0.001; Student's t-test.
Figure 7. Stable accumulation of oncogenic HMGA2 mediated by HBXIP promotes target gene expression and ESCC growth. (A) Real-time PCR analysis of HMGA2, HBXIP, cyclin A, SOX2, and hTERT mRNA levels in KYSE180 cells separately transfected with pCMV vectors, pCMV-HMGA2 vectors, or cotransfected with pCMV-HMGA2 and pSilencer-HBXIP vectors. Each bar shows the means ± SD (n = 3). (B) Monolayer colony-formation assay of KYSE180 cells transfected with the indicated plasmids. (C) EdU incorporation assays were used to assess EdU-positive cells among KYSE180 cells expressing the indicated vectors. Scale bars, 100 μm. (D) The curves of tumor growth in nude mice transplanted with KYSE180 cells is shown. Each bar shows the means ± SD (each group, n = 6). (E) Imaging of the tumors derived from nude mice transplanted with KYSE180 cells pretreated with indicated plasmids. (F) Weights of tumors in each group were shown. Each bar shows the means ± SD (each group, n = 6). (G) The expression levels of Ki67 and the statistics of Ki67-positive cells from above tumor tissues were examined by immunohistochemical assay. Scale bars, 50 μm. Each bar shows the means ± SD (n = 3). (H) The levels of HMGA2, HBXIP, CyclinA, SOX2 and hTERT from above tumor tissues were detected by western blotting. All experiments were repeated at least three times. Statistically significant differences are indicated: *P < 0.05, **P < 0.01 and ***P < 0.001; Student's t-test.CC BY-NC · PubMed Central
Figure 8. Aspirin attenuates ESCC growth by suppressing both HBXIP and HMGA2. (A) KYSE2 and KYSE450 cells were treated with different concentrations of aspirin (ASA) for 24 h. Endogenous HBXIP, HMGA2 and HMGA1 levels were examined by western blotting. (B) MTT assays with KYSE2 and KYSE450 cells separately treated with DMSO or ASA (2.5 mM) for the indicated periods. Each bar shows the means ± SD (n = 3). (C) Colony photograph and colony forming efficiency of KYSE2 and KYSE450 cells separately treated with DMSO or ASA (2.5 mM). Each bar shows the means ± SD (n = 3). (D) The imaging and the weights of tumors from saline- or ASA-treated groups were shown. Each bar shows the means ± SD (each group, n = 5). (E) The nude mice were subcutaneously injected with KYSE2 cells. After the tumour size exceeded 100 mm3, the mice were daily oral administrated with saline as the control or ASA (75mg/kg/day). The xenograft tumors were monitored for 4 weeks. The tumor growth curve of mice was shown. Each bar shows the means ± SD (each group, n = 5). (F) The expression levels of Ki67 and the statistics of Ki67-positive cells from above tumor tissues were examined by immunohistochemical assay. Scale bars, 50 μm. Each bar shows the means ± SD (n = 3). (G) The levels of HMGA2 K26 acetylation and the statistics of AcK26-HMGA2-positive cells from above tumor tissues were examined by immunohistochemical assay. Scale bars, 50 μm. Each bar shows the means ± SD (n = 3). (H) The levels of HMGA2, HBXIP and HMGA2 K26 acetylation from above tumor tissues were detected by western blotting. All experiments were repeated at least three times. Statistically significant differences are indicated: **P < 0.01, and ***P < 0.001; Student's t-test.
Figure 8. Aspirin attenuates ESCC growth by suppressing both HBXIP and HMGA2. (A) KYSE2 and KYSE450 cells were treated with different concentrations of aspirin (ASA) for 24 h. Endogenous HBXIP, HMGA2 and HMGA1 levels were examined by western blotting. (B) MTT assays with KYSE2 and KYSE450 cells separately treated with DMSO or ASA (2.5 mM) for the indicated periods. Each bar shows the means ± SD (n = 3). (C) Colony photograph and colony forming efficiency of KYSE2 and KYSE450 cells separately treated with DMSO or ASA (2.5 mM). Each bar shows the means ± SD (n = 3). (D) The imaging and the weights of tumors from saline- or ASA-treated groups were shown. Each bar shows the means ± SD (each group, n = 5). (E) The nude mice were subcutaneously injected with KYSE2 cells. After the tumour size exceeded 100 mm3, the mice were daily oral administrated with saline as the control or ASA (75mg/kg/day). The xenograft tumors were monitored for 4 weeks. The tumor growth curve of mice was shown. Each bar shows the means ± SD (each group, n = 5). (F) The expression levels of Ki67 and the statistics of Ki67-positive cells from above tumor tissues were examined by immunohistochemical assay. Scale bars, 50 μm. Each bar shows the means ± SD (n = 3). (G) The levels of HMGA2 K26 acetylation and the statistics of AcK26-HMGA2-positive cells from above tumor tissues were examined by immunohistochemical assay. Scale bars, 50 μm. Each bar shows the means ± SD (n = 3). (H) The levels of HMGA2, HBXIP and HMGA2 K26 acetylation from above tumor tissues were detected by western blotting. All experiments were repeated at least three times. Statistically significant differences are indicated: **P < 0.01, and ***P < 0.001; Student's t-test.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 47

Metadata

Authors
Wu, Y., Wang, X., Xu, F., Zhang, L., Wang, T., Fu, X., Jin, T., Zhang, W., & Ye, L.
Affiliations
Nankai University (CN)
Corresponding author
Ye, Lihong
Venue
Nucleic Acids Research
Published
2020-04-20
Volume
48
Issue
9
Pages
4858-4876
ISSN
  • 0305-1048 (ISSN-L)
  • 1362-4962
OpenAlex
W3017157136
Cited by
47
References
61
Citations by year
2026: 3 · 2025: 7 · 2024: 5 · 2023: 8 · 2022: 11 · 2021: 10 · 2020: 3
FWCI
7.30
Type
journal article
Language
en
Open access
Locations
  • Nucleic Acids Research (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Basic Research Program of China (2015CB553905)
  • National Natural Science Foundation of China (31670771, 31870752)
  • Fundamental Research Funds for the Central Universities
  • Ph.D. Candidate Research Innovation Fund of Nankai University
  • Project of Prevention and Control of Key Chronic Non-Infectious Diseases (2016YFC1303401)
Topics
  • Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords
HMGA2, HBXIP, esophageal squamous cell carcinoma, protein acetylation, PCAF, Akt signaling, protein stability, ubiquitination, proteasomal degradation, transcriptional coactivator, aspirin, tumor growth
MeSH terms
Esophageal Squamous Cell Carcinoma, p300-CBP-Associated Factor, Acetylation, Animals, Aspirin, DNA, Esophageal Neoplasms, Female, Humans, Lysine, Mice, Inbred BALB C, Mice, Nude, Prognosis, Protein Binding, Signal Transduction, Gene Expression Regulation, Neoplastic, HMGA2 Protein, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, p300-CBP Transcription Factors, Proto-Oncogene Proteins c-akt, Ubiquitination, Protein Stability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.